The ALRT (Defence Holdings PLC) share price is trading at 1.235p on the London Stock Exchange, representing a significant period of volatility with a 52-week range of 0.14p to 4.90p. The company currently maintains a market capitalization of approximately £30.42 million, with recent price action influenced by a major leadership transition and the ongoing rollout of its sovereign software capability.
In this exhaustive guide, you will explore the dual identity of the “ALRT” ticker, covering both the UK-listed Defence Holdings PLC and the US-based ALR Technologies SG (ALRTF). We deep-dive into Defence Holdings’ Project Ixian, its recent collaboration with Gloucestershire Police, and the appointment of Andrew Roughan as CEO effective March 30, 2026. Additionally, we analyze ALR Technologies’ relaunch of the GluCurve Pet CGM in early 2026. Whether you are tracking the high-growth potential of AI-driven defence or the niche medical device market, this article provides the authoritative, factual data required for informed decision-making.
Current Market Status: Defence Holdings (UK)
Defence Holdings PLC, trading under the ticker ALRT on the London Stock Exchange, is currently navigating a pivotal phase of corporate maturation. As of the market close on March 27, 2026, the stock settled at 1.235p, showing a modest recovery from a weekly low of 1.10p. The company is classified within the Aerospace & Defense sub-sector, focusing on AI-driven analytics and secure communications.
The stock’s performance in early 2026 has been characterized by high volume, with daily trades often exceeding 15 million shares. Investors are reacting to the company’s aggressive pivot toward “National Security” as a primary business pillar. While the share price remains 75% below its October 2025 peak of 4.90p, the current valuation reflects a stabilization following the announcement of a new CEO and the advancement of Project Ixian.
ALR Technologies: US Market Overview
While the ALRT ticker represents a defence firm in London, it also belongs to ALR Technologies SG (ALRTF) on the OTC markets in the United States. This Singapore-headquartered medical device company is currently valued at approximately $17.3 million, with its stock trading around $0.01. The US-listed entity focuses exclusively on diabetes management and pet health technology.
In early 2026, ALRTF made headlines with the official relaunch of the GluCurve Pet CGM, a continuous glucose monitor for cats and dogs. The company entered a strategic relationship with a leading veterinary distributor for a US rollout planned for Q2 2026. This healthcare division operates entirely independently of the UK-listed defence entity, making it crucial for investors to distinguish between the two when analyzing “ALRT” share news.
Strategic Leadership: The New CEO
A major catalyst for the UK’s ALRT share price in 2026 is the appointment of Andrew Roughan as Chief Executive Officer, officially starting on March 30, 2026. Roughan brings extensive experience from the tech infrastructure and sovereign data sectors. His arrival is widely viewed as a move to institutionalize the company’s “Sovereign Software Capability Accelerator.”
The market responded to this appointment with cautious optimism, as Roughan’s background aligns with NVIDIA-partnered projects and high-scale digital transformation. His primary task for the remainder of 2026 will be converting the company’s current “pre-contract pathways” into binding revenue. Investors are specifically watching for updates on the “ATM” (At-The-Market) funding facility, which the new CEO is expected to manage to ensure capital efficiency.
Project Ixian and AI Momentum
Defence Holdings’ flagship initiative, Project Ixian, has progressed to the final contract stages with its first major customer as of early 2026. This project leverages AI-driven reasoning technology to provide operational advantages in land, sea, and space domains. In late 2025, the company selected Google Cloud as its hyperscale provider, ensuring the infrastructure meets sovereign security requirements.
The “Ixian” platform is designed to automate sensor data analysis for national security agencies. Recent updates indicate that the second build of its “Classified AI Product” was completed in February 2026. This momentum has kept the stock on the radar of small-cap tech investors, as the company seeks to move from R&D-heavy operations to a commercially viable software-as-a-service (SaaS) model for defence.
Collaboration with Gloucestershire Police
On December 30, 2025, Defence Holdings announced a strategic collaboration with Gloucestershire Police, marking its first major foray into domestic national security. This partnership focuses on using AI-driven analytics to enhance public safety and criminal investigations. The move was a primary driver for the stock’s surge in early January 2026, as it demonstrated the tech’s cross-sector utility.
The collaboration serves as a “living lab” for the company’s national security pillar. Success in this regional partnership is intended to serve as a blueprint for wider deployment across UK police forces and Home Office agencies. Analysts believe that securing additional domestic security contracts will be essential for the share price to regain its former highs above 3.00p.
Financial Performance and AUMA
According to the unaudited interim results for the period ended September 30, 2025, Defence Holdings reported a loss before tax of £1.04 million. While the company is currently loss-making, its revenue generation is shifting toward high-margin software licenses rather than hardware. The company maintains a healthy free float of approximately 2.23 billion shares.
For the US entity (ALRTF), financial reports indicate a trailing 12-month revenue of approximately $40 million as of the Singapore migration merger. The relaunch of the GluCurve product is projected to contribute significantly to the 2026 top line, with a potential market size estimated between 150,000 and 300,000 units annually in Canada alone.
Practical Information for Investors
NVIDIA’s UK-listed ALRT (Defence Holdings) is primarily traded on the London Stock Exchange (LSE). Trading hours follow standard UK market times, providing liquidity for both institutional and retail investors.
- Trading Hours: Monday–Friday, 08:00 – 16:30 GMT.
- Minimum Trade Size: Typically 1 share, though EMS (Exchange Market Size) is 500,000.
- Settlement: T+2 (Standard UK settlement).
- Brokerage Access: Available via Hargreaves Lansdown, AJ Bell, and interactive investor.
- ISIN: GB00BMWVF760.
What drives the Alrt share price
Defence contracts and government programmes
The core driver of the Alrt share price is the pipeline of defence and government‑related contracts that Defence Holdings secures or expects to secure. As a UK‑listed defence‑technology firm, ALRT’s valuation is tied closely to:
- Win rates on tenders and task‑order competitions,
- Order size and duration, and
- Geographic diversification across allied‑defence programmes.
Any confirmation of a new multi‑year programme, a sovereign‑AI‑based project, or a follow‑on contract update can push the Alrt share price sharply higher, especially if the announcement signals recurring revenue and a clear path to scaling the business. Conversely, a loss of a key contract, a delay in programme approval, or any sign that the company’s technology is not gaining traction can trigger a rapid sell‑off.
Because Defence Holdings operates in a high‑regulation, long‑sales‑cycle environment, news is often lumpy, and the Alrt share price can remain quiet for extended periods before erupting on a single announcement. This makes it a classic “event‑risk, event‑reward” stock for traders and long‑term investors.
Technology and AI‑sovereign positioning
Another key influence on the Alrt share price is the market’s view of Defence Holdings’ sovereign‑AI and defence‑technology platforms. If investors see the company as:
- Pioneering or differentiated in AI‑aided defence‑planning and battlefield analytics, or
- Gaining traction with allied‑government partners on AI‑enabled solutions,
the stock tends to trade at a higher valuation multiple than pure‑hardware or legacy‑defence suppliers. Positive commentary about the maturity of its software stack, the number of live pilots, and the potential for export‑sale agreements can all support a higher share price.
On the flip side, if peers launch similar products more quickly, if regulatory or ethical concerns around defence‑AI intensify, or if the government‑funding environment tightens, the Alrt share price can compress back toward lower‑valuation bands. This duality means that the technological narrative is as important as the hard financials for this stock.
Market sentiment and sector rotation
Even without company‑specific news, the Alrt share price can move on broader market factors:
- Defence‑sector sentiment: When global defence stocks rally on geopolitical tensions or higher spending announcements, ALRT often follows.
- Risk‑on vs. risk‑off: As a small‑cap growth‑style stock, ALRT tends to underperform in risk‑off periods and outperform when investors chase higher‑beta names.
- Currency and interest‑rate backdrop: A weaker sterling can make UK‑listed defence‑tech stocks relatively more attractive to foreign investors, while higher rates can weigh on loss‑making or pre‑profit names.
These macro and sector‑level drivers explain why the Alrt share price sometimes trends up or down for weeks without a specific Defence Holdings headline. Understanding where the stock sits in the broader defence and small‑cap technology context helps gauge whether moves are driven by company‑specific events or sector‑wide rotation.
ALRT business model and fundamentals
Core business segments
Defence Holdings operates as a defence‑technology group with a focus on AI‑driven decision‑support and defence‑analytics products. Its business model centres on:
- Software and platform sales to defence‑related agencies and allied governments,
- Subscription‑style contracts or service‑contracts where the customer pays for access or usage over time, and
- Project‑based consulting and integration work around AI‑enabled defence systems.
While the company may also derive some revenue from hardware‑integration or managed‑services contracts, the strategic emphasis appears to be on scalable software and AI‑based solutions that can be reused across multiple programmes and borders.
Revenue, profitability, and scale
Defence Holdings is a small‑cap with limited revenue relative to larger defence contractors. Financial disclosures suggest annual revenue on the order of single‑digit millions of pounds, with margins that are thin or negative because of the upfront R&D and sales‑cycle costs typical of early‑stage defence‑software companies.
Key characteristics for the Alrt share price include:
- Low absolute revenue scale but high growth optionality if the company wins meaningful follow‑on contracts.
- Limited or negative earnings, which means traditional value‑style metrics (like earnings‑based valuation) are less relevant than pipeline and contract wins.
- Market capitalisation that remains modest compared with major defence primes, keeping ALRT in the high‑risk, high‑upside bracket.
Investors therefore tend to price ALRT as a leveraged bet on future defence‑software and AI contracts rather than a steady, dividend‑paying defence stock.
Frequently Asked Questions
What is the ALRT share price today?
As of March 28, 2026, the Defence Holdings (ALRT) share price is approximately 1.235p (LSE), while the ALR Technologies (ALRTF) price is approximately $0.012 (OTC).
Who is the new CEO of Defence Holdings?
Andrew Roughan, former CEO of Plexal, officially assumed the role of CEO on March 30, 2026, to lead the company’s commercial expansion in the defence sector.
When is the GluCurve U.S. launch?
The U.S. relaunch of the GluCurve Pet CGM is scheduled for early Q2 2026, following its successful release in the Canadian market in January.
Is Project Ixian generating revenue yet?
As of Q1 2026, Project Ixian is in the final stages of contract finalization with its first major customer, moving from a pre-contract pathway to active commercialization.
What are the exercise prices for the new CEO’s warrants?
Andrew Roughan’s warrants are structured in three tranches with exercise prices of 1.38p, 3.45p, and 6.90p, aligning his incentives with significant share price growth.
How much capital has the ATM facility raised?
As of February 2026, Defence Holdings has raised total gross proceeds of approximately £754,567 through its at-the-market (ATM) funding facility.
What is the “Sovereign Software Capability Accelerator”?
Launched in February 2026, this program is designed to fast-track AI and software prototypes into “Defence-ready” deployable assets for the UK and its allies.
Does ALRT have any government partnerships?
Yes, Defence Holdings has a strategic collaboration with Gloucestershire Police and is working within NATO frameworks for its AI development.
What is the market cap of Defence Holdings?
The current market capitalization for the UK-listed entity is approximately £30.42 million, based on a share price of 1.235p.
Can I buy ALRT on a standard UK brokerage?
Yes, Defence Holdings (ALRT) is listed on the London Stock Exchange and is available through major UK brokers like Hargreaves Lansdown and AJ Bell.
What is the estimated market size for GluCurve in the US?
ALR Technologies estimates the potential U.S. market for the GluCurve Pet CGM to be between 2 million and 3 million units per year.
Final Thoughts
As of late March 2026, the trajectory for the “ALRT” ticker is split between two distinct geographic and industrial stories. In the United Kingdom, Defence Holdings PLC has successfully navigated its transition from a speculative venture to a structured defence contractor. The appointment of Andrew Roughan as CEO, effective March 30, 2026, marks the beginning of a “commercial delivery” phase, as the company seeks to monetize Project Ixian and its Sovereign Software Capability Accelerator. While the share price remains sensitive to funding updates from its ATM facility, the recent 13% surge in late March suggests that institutional confidence is building around its NATO-aligned AI strategies.
Across the Atlantic, ALR Technologies SG (ALRTF) is entering its most critical product cycle to date. The successful relaunch of the GluCurve Pet CGM in Canada in early 2026 has set the stage for a high-stakes U.S. rollout in Q2 2026. With an estimated market potential of up to 3 million units in the United States alone, the company’s valuation is heavily tied to its ability to secure wider distribution through its partnership with major veterinary distributors. For investors, the “ALRT” story in 2026 is one of execution: one in the high-security realm of sovereign defence, and the other in the rapidly growing niche of specialized animal healthcare technology.
Read More on Newcastle Reporter